Project Grant R43AI188970
Award Date 8/19/25
Completion Date 7/31/27
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $420,771 Project Grant to the Regents of the University of Minnesota, Office of Sponsored Projects Administration, under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The grant aims to develop targeted genetic therapies for Artemis-deficient severe combined immunodeficiency (ART-SCID), a rare and life-threatening primary immune disorder. The research focuses on using adenosine base...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $307,091 Project Grant to Aleutian Therapeutics, Inc. under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The objective of this Phase I research is to develop immune evasive strategies for allogeneic (non-self) cell replacement therapies, specifically by ascertaining the minimal number of genetic edits required to enable human pluripotent stem cells to overcome xenogeneic...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Emmune Inc., a biotechnology company based in Cambridge, Massachusetts. The grant will support pre-clinical IND-enabling studies for a long-acting recombinant protein therapeutic called ECD4-IG, which is being developed as a potential treatment for HIV. The key activities include conducting in vitro assays...
- This Project Grant award of $3,192,404 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research on immunomodulation in adeno-associated virus (AAV) gene therapy. The research aims to better understand, model, and manage immune responses that can arise from systemic dosing of recombinant AAV vectors, which pose a major challenge in the treatment of monogenic disorders using this gene...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,017,032 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Scripps Research Institute. The grant supports research to develop a single-shot sequential immunization regimen for HIV using atomic layer deposition (ALD) technology. The project aims to create a vaccine capable of eliciting broadly neutralizing antibodies (bNAbs) to provide effective protection...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $605,895 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Rutgers, The State University to conduct research on cryogenic nanoimaging of adeno-associated virus (AAV) infection and packaging. The project aims to directly observe key steps in AAV infection and transduction using cryo-electron microscopy techniques, in order to determine the structural basis for barriers...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $506,000 Project Grant titled "Development of siRNA-Peptide Libraries for Delivery Screening" to the Scripps Research Institute in California. This 2-year grant, running from Jul 9, 2025 to Jun 30, 2027, aims to develop high-throughput technologies for generating and screening siRNA-peptide conjugates to improve the delivery efficiency of small interfering RNA (siRNA) therapeutics. The goal is to address key...
- The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $999,991 Project Grant to Tendel Therapies Inc. on August 13, 2025. The grant supports the development of an HIV reservoir-depletion agent, BSAB-98, a bispecific antibody that targets CCR5-expressing cells for elimination. Preclinical studies in infant rhesus macaques showed over 50% remission of simian immunodeficiency virus (SIV) after BSAB-98...
- This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...